GlaxoSmithKline Spends $3.3 Billion to Catch up in Vaccination Arms Race - Gizmodo

Affinivax's latest vaccine fights pneumonia, meningitis, and bloodstream infections.

UK-based drug company GlaxoSmithKline will buy Boston-based vaccine developer Affinivax for $2.1 billion, according to press releases issued by the two companies early Tuesday. GSK will also pay up t… [+2616 chars]

full article...